FERACCRU® (ferric maltol) 30 mg hard capsules
Information intended for UK healthcare professionals only. This formulary decision guide is promotional and was developed from content provided by Norgine Pharmaceuticals Limited in a format developed by Guidelines in Practice (contains promotional information).
View FERACCRU® (ferric maltol) prescribing information and adverse event reporting information here
UK-HAE-FER-2100127
Date of preparation: December 2021
Jardiance® (empagliflozin) film-coated tablets for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)
This formulary decision guide was commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105819 October 2021
Klisyri▼ (tirbanibulin) 10 mg/g ointment
This formulary decision guide was developed from content provided by Almirall Ltd in a format developed by Guidelines in Practice. It was commissioned by Almirall Ltd, who carried out full medical approval to ensure compliance with regulations.
View prescribing and adverse event reporting information
UK-KLI-2100017 | Date of preparation: October 2021
Sixmo®▼ (buprenorphine) 74.2 mg implant
Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by Accord Healthcare Limited in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting information.
UK-03417
Date of preparation: October 2021
Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13 Date of preparation: September 2021
Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20 Date of preparation: July 2021
Steglatro®▼ (Ertugliflozin)
This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
Prescribing Information (Great Britain) & (Northern Ireland), and Adverse Event Reporting Information
GB-STE-00433 | June 2021
Trurapi▼ (insulin aspart 100 units/ml)
This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021